TY - JOUR
T1 - Mobile technology offers novel insights on control and treatment of allergic rhinitis. The MASK study
AU - MASK study group
AU - Bédard, Annabelle
AU - Basagaña, Xavier
AU - Anto, Josep M
AU - Garcia-Aymerich, Judith
AU - Devillier, Philippe
AU - Arnavielhe, Sylvie
AU - Bedbrook, Anna
AU - Onorato, Gabrielle L
AU - Czarlewski, Wienczyslawa
AU - Murray, Ruth
AU - Almeida, Rute
AU - Fonseca, Joao
AU - Costa, Elisio
AU - Malva, Joao
AU - Morais-Almeida, Mario
AU - Pereira, Ana Maria
AU - Todo-Bom, Ana
AU - Menditto, Enrica
AU - Stellato, Cristiana
AU - Ventura, Maria Teresa
AU - Cruz, Alvaro A
AU - Stelmach, Rafaël
AU - da Silva, Jane
AU - Larenas-Linnemann, Désirée
AU - Fuentes-Pérez, José M
AU - Huerta-Villalobos, Yunuen R
AU - Emuzyte, Regina
AU - Kvedariene, Violeta
AU - Valiulis, Arunas
AU - Kuna, Piotr
AU - Samolinski, Boleslaw
AU - Klimek, Ludger
AU - Mösges, Ralph
AU - Pfaar, Oliver
AU - Shamai, Sara
AU - Annesi-Maesano, Isabelle
AU - Bosse, Isabelle
AU - Demoly, Pascal
AU - Fontaine, Jean-François
AU - Cardona, Vicky
AU - Mullol, Joaquim
AU - Valero, Antonio
AU - Roller-Wirnsberger, Regina E
AU - Tomazic, Peter Valentin
AU - Chavannes, Niels H
AU - Fokkens, Wytske J
AU - Reitsma, Sietze
AU - Bewick, Mike
AU - Ryan, Dermot
AU - Sheikh, Aziz
N1 - Copyright © 2019. Published by Elsevier Inc.
PY - 2019/4/3
Y1 - 2019/4/3
N2 - BACKGROUND: Mobile health may be used to generate innovative insights into optimizing treatment to improve allergic rhinitis control.OBJECTIVES: A cross-sectional real world observational study was undertaken in 22 countries to complement a pilot study and bring novel information on medication use, disease control and work productivity in everyday life of patients with allergic rhinitis.METHODS: A mobile phone app (Allergy Diary, freely available Google Play and Apple stores) was used to collect data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all allergy medications (prescribed and over-the-counter (OTC)) customized for 22 countries. The four most common intra-nasal medications containing intra-nasal corticosteroids and eight oral H1-antihistamines were studied.RESULTS: 9,122 users filled in 112,054 days of VAS in 2016 and 2017. The assessment of days was informative. The control of days with rhinitis differed between no [best control], single [good control for intranasal corticosteroid-treated days] or multiple treatments [worst control]. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms and work productivity. Differences between oral H1-antihistamines were found.CONCLUSIONS: This study confirms the usefulness of the Allergy Diary in accessing and assessing patient behavior in allergic rhinitis. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible.
AB - BACKGROUND: Mobile health may be used to generate innovative insights into optimizing treatment to improve allergic rhinitis control.OBJECTIVES: A cross-sectional real world observational study was undertaken in 22 countries to complement a pilot study and bring novel information on medication use, disease control and work productivity in everyday life of patients with allergic rhinitis.METHODS: A mobile phone app (Allergy Diary, freely available Google Play and Apple stores) was used to collect data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all allergy medications (prescribed and over-the-counter (OTC)) customized for 22 countries. The four most common intra-nasal medications containing intra-nasal corticosteroids and eight oral H1-antihistamines were studied.RESULTS: 9,122 users filled in 112,054 days of VAS in 2016 and 2017. The assessment of days was informative. The control of days with rhinitis differed between no [best control], single [good control for intranasal corticosteroid-treated days] or multiple treatments [worst control]. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms and work productivity. Differences between oral H1-antihistamines were found.CONCLUSIONS: This study confirms the usefulness of the Allergy Diary in accessing and assessing patient behavior in allergic rhinitis. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible.
U2 - 10.1016/j.jaci.2019.01.053
DO - 10.1016/j.jaci.2019.01.053
M3 - Article
C2 - 30951790
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
ER -